Table 2 Metastatic disease locations and median lesion SUVmax for each patient
Patient # | Tumor type | Disease locations | PSMA median SUVmax (range) | FDG median SUVmax (range) | Neck MRI findings | Liver SUVmax | PSMA > liver + No FDG/PSMA discordance? |
|---|---|---|---|---|---|---|---|
1 | PTC | B | 9.0 (1.0–10.1) | 21.1 (4.1–28.4) | Post-tx, bone mets (P,F) | 7.2 | Yes |
2 | HCC | B, ST | 11.0 (3.4–27.8) | 11.6 (4.7–31.3) | Post-tx, bone mets (F) | 13.2 | Yes |
3 | PDPTC | ST | 4.5 (1.9–6.2) | 5.3 (4.1–10.3) | Post-tx (non-avid) | 5.6 | Yes |
4 | ATC | ST, TB | 3.3 (1.6–6.0) | 14.3 (4.2–19.1) | Post-tx, “treated” residual TB tissue (P,F) | 9.5 | No |
5 | FTC | B | 15.0 (15.0–15.0) | 3.5 (3.5–3.5) | Post-tx (non-avid) | 6.5 | Yes |
6 | PDPTC | LN, ST, TB | 8.5 (4.3–12.6) | 4.1 (2.6–5.6) | Post-tx (P,F) | 10.2 | Yes |
7 | PTC | ST | 2.7 (2.7–2.7) | 17.0 (17.0–17.0) | Post-tx (non-avid) | 9.2 | No |
8 | ATC | TB | 6.0 (5.7–6.3) | 14.1 (13.8–14.3) | Post-tx, TB soft tissue (P,F) | 5.7 | Yes |
9 | PTC | LN | 2.5 (2.0–11.4) | 5.9 (5.3–6.9) | Post-tx, decreasing cervical LN (F) | 7.1 | Yes |
10 | FTC | B | 13.8 (9.2–18.3) | 8.0 (7.4–8.7) | Post-tx (non-avid) | 5.4 | Yes |
11 | HCC | ST | 2.8 (2.5–3.1) | 4.3 (3.9–4.7) | Post-tx (non-avid) | 13.9 | No |